Drug information
Molnupiravir capsule 200 mg (Dr.Reddy's)
Indications
Treatment of COVID-19 in patients who were 18 years of age and older. Click to listen highlighted text! Indications Treatment of COVID-19 in patients who were 18 years of age and older.
Contraindications and precautions
1.Molnupiravir is contraindicated in patients with a history of clinically significant hypersensitivity to the active substance or to any of the excipients.
2.Molnupiravir is not recommended for use during pregnancy as safety data are not established. When considering Molnupiravir for pregnant individual, the prescribing healthcare provider must communicate the known and potential benefits and the potential risks of using Molnupiravir during pregnancy to the pregnant individual.
3.Females of childbearing potential: Use a reliable method of contraception correctly and consistently, as applicable during treatment and for 4 days after final dose
4.Breastfeeding is not recommended during treatment with Molnupiravir and for 4 days after the final dose because of the potential for adverse reactions in the infant from Molnupiravir.
5.Males with partners of childbearing potential: Use a reliable method of contraception correctly and consistently during treatment and for at least 3 months after final dose; risk beyond 3 months after last dose is unknown; studies on the risks >3 months are ongoing
6.Molnupiravir is not authorized for use in patients less than 18 years of age because it may affect bone and cartilage growth.
7.Not recommend prescribing Andrographis Paniculata (Far Ta Lai Jone) and antiviral for treatment of COVID-19. Click to listen highlighted text! Contraindications and precautions 1.Molnupiravir is contraindicated in patients with a history of clinically significant hypersensitivity to the active substance or to any of the excipients. 2.Molnupiravir is not recommended for use during pregnancy as safety data are not established. When considering Molnupiravir for pregnant individual, the prescribing healthcare provider must communicate the known and potential benefits and the potential risks of using Molnupiravir during pregnancy to the pregnant individual. 3.Females of childbearing potential: Use a reliable method of contraception correctly and consistently, as applicable during treatment and for 4 days after final dose 4.Breastfeeding is not recommended during treatment with Molnupiravir and for 4 days after the final dose because of the potential for adverse reactions in the infant from Molnupiravir. 5.Males with partners of childbearing potential: Use a reliable method of contraception correctly and consistently during treatment and for at least 3 months after final dose; risk beyond 3 months after last dose is unknown; studies on the risks >3 months are ongoing 6.Molnupiravir is not authorized for use in patients less than 18 years of age because it may affect bone and cartilage growth. 7.Not recommend prescribing Andrographis Paniculata (Far Ta Lai Jone) and antiviral for treatment of COVID-19.
Recommendations of drug use
1.This medication can be taken with or without food.
2.The capsules should be swallowed whole with a glass of water.
The capsules should not be opened, crushed or chewed.
3.In case of the patient misses a dose of Molnupiravir:
3.1) If the patient misses a dose within 10 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule.
3.2) If the patient misses a dose by more than 10 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double the dose.
4.To ensure expected therapeutic effect, Molnupiravir should be givenc within 5 days of symptom onset. Click to listen highlighted text! Recommendations of drug use 1.This medication can be taken with or without food. 2.The capsules should be swallowed whole with a glass of water.The capsules should not be opened, crushed or chewed. 3.In case of the patient misses a dose of Molnupiravir: 3.1) If the patient misses a dose within 10 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule. 3.2) If the patient misses a dose by more than 10 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double the dose. 4.To ensure expected therapeutic effect, Molnupiravir should be givenc within 5 days of symptom onset.
Adverse Reactions
This medication may cause diarrhea, nausea, dizziness. Click to listen highlighted text! Adverse Reactions This medication may cause diarrhea, nausea, dizziness.
Drug storage
Store between 20-25 degrees Celsius. Click to listen highlighted text! Drug storage Store between 20-25 degrees Celsius.
The above information is drug information used for patient self-care only.
If you have any inquiries, please ask your physicians or pharmacists. Click to listen highlighted text! The above information is drug information used for patient self-care only. If you have any inquiries, please ask your physicians or pharmacists.
ที่มาของข้อมูล
-เอกสารกำกับยาภาษาไทย ลาเกฟรีโอ 200 มิลลิกรัม
-แนวทางเวชปฏิบัติ การวินิจฉัย ดูแลรักษา และป้องกันการติดเชื้อในโรงพยาบาล กรณีโรคติดเชื้อไวรัสโคโรนา 2019 (COVID-19) ฉบับปรับปรุง วันที่ 11 กรกฎาคม พ.ศ.2565 สำหรับแพทย์และบุคลากรสาธารณสุข [Internet]. 2022 [cited 2022 Aug 19]. Available from:https://covid19.dms.go.th/backend/Content/Content_FIle/Bandner_(Big)/Attach/25650712141035PM_CPG_COVID-19_v.24.1.n_20220711.pdf.